Sunil S. Badve
#147,974
Most Influential Person Now
Cancer researcher, pathologist
Sunil S. Badve's AcademicInfluence.com Rankings
Sunil S. Badvelaw Degrees
Law
#2636
World Rank
#3277
Historical Rank
Common Law
#122
World Rank
#131
Historical Rank
Sunil S. Badvebiology Degrees
Biology
#10861
World Rank
#14220
Historical Rank
Pathology
#144
World Rank
#268
Historical Rank
Download Badge
Law Biology
Sunil S. Badve's Degrees
- PhD Pathology Purdue University
Why Is Sunil S. Badve Influential?
(Suggest an Edit or Addition)Sunil S. Badve's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (3403)
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. (2015) (1875)
- Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer (2018) (1273)
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. (2015) (1097)
- Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. (2014) (1004)
- CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis (2006) (983)
- Derivation of hepatocytes from bone marrow cells in mice after radiation‐induced myeloablation (2000) (969)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). (2010) (760)
- Breast cancer prognostic classification in the molecular era: the role of histological grade (2010) (749)
- Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia (2009) (730)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (668)
- Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists (2011) (629)
- Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. (2008) (611)
- NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2 (2007) (601)
- A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. (2007) (514)
- A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast (2013) (476)
- Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe (2017) (408)
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. (2019) (345)
- Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. (2008) (326)
- Phyllodes tumours of the breast: a consensus review (2016) (305)
- Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells (2005) (277)
- Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. (2017) (270)
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. (2019) (269)
- FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival (2007) (248)
- Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. (2008) (230)
- Radiation pneumonitis in mice: a severe injury model for pneumocyte engraftment from bone marrow. (2002) (223)
- Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. (2015) (223)
- ITMIG Consensus Statement on the Use of the WHO Histological Classification of Thymoma and Thymic Carcinoma: Refined Definitions, Histological Criteria, and Reporting (2014) (217)
- An international study to increase concordance in Ki67 scoring (2015) (211)
- The Integrated Genomic Landscape of Thymic Epithelial Tumors. (2018) (210)
- Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group (2020) (207)
- Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment (2010) (196)
- Towards Large-Scale Histopathological Image Analysis: Hashing-Based Image Retrieval (2015) (195)
- Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group (2016) (189)
- Computerized classification of intraductal breast lesions using histopathological images (2011) (187)
- Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group (2015) (182)
- SLUG/SNAI2 and Tumor Necrosis Factor Generate Breast Cells With CD44+/CD24- Phenotype (2010) (178)
- Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. (2016) (178)
- The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer (2005) (170)
- Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. (2015) (163)
- Breast-cancer stem cells-beyond semantics. (2012) (154)
- Telomerase Template Antagonist GRN163L Disrupts Telomere Maintenance, Tumor Growth, and Metastasis of Breast Cancer (2006) (140)
- Morphological Changes in Breast Tissue with Menstrual Cycle (2002) (138)
- Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry (2008) (138)
- Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse (2012) (134)
- Tumor Heterogeneity in Breast Cancer (2015) (130)
- Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects. (1995) (129)
- FOXA1 is an independent prognostic marker for ER-positive breast cancer (2012) (124)
- Breast cancer stem cells and intrinsic subtypes: controversies rage on. (2009) (124)
- Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22 (2011) (117)
- Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry (2013) (117)
- Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration (2016) (116)
- Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis (2007) (116)
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. (2020) (113)
- A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker (2006) (111)
- The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice (2020) (108)
- The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort (2010) (107)
- Atypical ductal hyperplasia: interobserver and intraobserver variability (2011) (106)
- Effects of HIV Protease Inhibitor Ritonavir on Akt-Regulated Cell Proliferation in Breast Cancer (2006) (106)
- Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. (2018) (105)
- Solitary myofibroma in adults: clinicopathological analysis of a series (1993) (103)
- ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. (2013) (102)
- AKT Alters Genome-Wide Estrogen Receptor α Binding and Impacts Estrogen Signaling in Breast Cancer (2008) (100)
- Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases (2008) (100)
- Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. (2008) (99)
- Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long follow-up. (1998) (96)
- Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications (2008) (93)
- Pathogenesis of gastric metaplasia of the human duodenum: role of Helicobacter pylori, gastric acid, and ulceration. (1996) (93)
- Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients (2011) (93)
- Pregnancy after breast cancer: if you wish, ma’am (2011) (87)
- Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue (2007) (87)
- Spontaneous Mammary Intraepithelial Lesions in Dogs—A Model of Breast Cancer (2007) (85)
- Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. (2020) (85)
- Lymphangiogenesis Does Not Occur in Breast Cancer (2005) (83)
- Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. (2008) (83)
- Microsomal prostaglandin E2 synthase‐1 in breast cancer: a potential target for therapy (2006) (81)
- Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast (2006) (77)
- FOXA1 as a therapeutic target for breast cancer (2007) (76)
- Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma. (2002) (73)
- NuMA influences higher order chromatin organization in human mammary epithelium. (2006) (71)
- Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study (2012) (71)
- A Phase II Study of Single Agent Bortezomib in Patients with Metastatic Breast Cancer: A Single Institution Experience (2007) (70)
- Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models (2012) (68)
- High‐level expression of forkhead‐box protein A1 in metastatic prostate cancer (2011) (66)
- Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer (2016) (66)
- Expression of androgen receptor and prostate-specific antigen in male breast carcinoma (2003) (66)
- Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options. (2015) (64)
- Interleukin-1α promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer (2003) (64)
- FOXA1 in breast cancer (2009) (63)
- DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer. (2014) (61)
- Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure (2003) (61)
- Pseudoangiomatous hyperplasia of male breast (1995) (61)
- Prognostic Impact of HOTAIR Expression is Restricted to ER-Negative Breast Cancers (2015) (60)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
- Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity (2013) (59)
- MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB–NFIB fusion gene (2018) (58)
- Thymic carcinoma: outcomes after surgical resection. (2012) (58)
- PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer (2011) (58)
- Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer (2018) (58)
- Extrathoracic metastases of thymic origin: a review of 35 cases (2012) (58)
- Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database (2017) (55)
- Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores (2010) (55)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (54)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
- Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration (2019) (54)
- Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. (2011) (54)
- Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast (2010) (50)
- Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC) (2015) (49)
- Personalized medicine: the road ahead. (2011) (49)
- Prognostic indicators after surgery for thymoma. (2010) (48)
- Pro‐inflammatory angiogenesis is mediated by p38 MAP kinase (2011) (47)
- Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial (2013) (47)
- Prediction of Postoperative Recurrence-Free Survival in Non–Small Cell Lung Cancer by Using an Internationally Validated Gene Expression Model (2011) (47)
- Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. (1995) (46)
- Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies (2018) (46)
- The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells. (2005) (46)
- Role of E‐cadherins in development of lymphatic tumor emboli (2003) (46)
- Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. (2003) (45)
- Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells (2015) (44)
- Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146. (2015) (44)
- Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. (2010) (44)
- Splicing factor ESRP1 controls ER‐positive breast cancer by altering metabolic pathways (2019) (44)
- NF-κB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT (2015) (44)
- A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer (2012) (44)
- Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank (2014) (43)
- WHO types A and AB thymomas: not always benign (2010) (42)
- Impact of Preanalytic Factors on the Design and Application of Integral Biomarkers for Directing Patient Therapy (2012) (41)
- Assessment of Utility of Ductal Lavage and Ductoscopy in Breast Cancer—A Retrospective Analysis of Mastectomy Specimens (2003) (41)
- The role of histology in predicting recurrence of type A thymomas: a clinicopathologic correlation of 23 cases (2013) (41)
- A Multiple Instance Learning Approach toward Optimal Classification of Pathology Slides (2010) (40)
- Phyllodes tumors of the breast (2001) (40)
- Role of Helicobacter pylori serology in screening prior to endoscopy (1992) (40)
- Effect of Helicobacter pylori eradication on gastric metaplasia of the duodenum. (1995) (40)
- Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer (2011) (39)
- A mechanism of drug resistance to tamoxifen in breast cancer (2002) (39)
- Expression of trefoil peptides pS2 and human spasmolytic polypeptide in gastric metaplasia at the margin of duodenal ulcers. (1995) (39)
- Molecular Analysis of Thymoma (2012) (38)
- S4-6: A Quantitative Multigene RT-PCR Assay for Predicting Recurrence Risk after Surgical Excision Alone without Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective Validation Study of the DCIS Score from ECOG E5194. (2011) (38)
- A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas (2016) (38)
- Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105. (2014) (36)
- Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. (2020) (36)
- Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory (2004) (36)
- CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer (2021) (36)
- Single cell heterogeneity in ductal carcinoma in situ of breast (2017) (35)
- Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer (2015) (35)
- Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients (2015) (34)
- Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration (2016) (34)
- Abstract S1-03: Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy (2016) (34)
- Immunolocalization of low-affinity prostaglandin E receptors, EP and EP, in adult human epidermis. (2005) (34)
- Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management (2016) (34)
- Micronodular thymic neoplasms: case series and literature review with emphasis on the spectrum of differentiation (2015) (34)
- 20. Thymoma and Thymic Carcinoma (2012) (33)
- Prevalence and Classification of Spontaneous Mammary Intraepithelial Lesions in Dogs Without Clinical Mammary Disease (2010) (33)
- Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing (2013) (32)
- TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis (2015) (32)
- A Physiologic Imaging Pilot Study of Breast Cancer Treated with AZD2171 (2006) (32)
- Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes (2006) (31)
- Prostanoid receptor EP1 expression in breast cancer (2008) (31)
- Ductal carcinoma in situ of breast: update 2019. (2019) (31)
- Tumor-In fi ltrating Lymphocytes and Prognosis : A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers (2019) (31)
- Podoplanin, a novel marker for seminoma: A comparison study evaluating immunohistochemical expression of podoplanin and OCT3/4. (2010) (31)
- Role of lncRNAs in health and disease-size and shape matter. (2015) (30)
- Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet. (2010) (30)
- Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues (2019) (29)
- Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer. (2019) (29)
- Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. (2011) (29)
- Benign glandular inclusions a rare cause of a false positive sentinel node (2007) (29)
- Histologie Distribution and Biochemical Properties of α1‐Microglobulin in Human Placenta (1999) (28)
- Molecular profiling assays in breast cancer: are we ready for prime time? (2012) (28)
- Abstract S1-06: Stromal tumor-infiltrating lymphocytes(S-TILs): In the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit (2015) (27)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (27)
- Small Cells in Hepatoblastoma Lack “Oval” Cell Phenotype (2003) (27)
- Effect of Time Interval on Residual Disease in Breast Cancer (2003) (26)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (26)
- Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model. (2010) (26)
- Upregulation of HSF1 in estrogen receptor positive breast cancer (2016) (26)
- A Gene Signature to Determine Metastatic Behavior in Thymomas (2013) (26)
- Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer (2009) (25)
- Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC): Hoosier Oncology Group BRE09-146. (2014) (24)
- A case of Warthin's tumour with coexistent Hodgkin's disease (1993) (24)
- Lymphatic vessel density in radical prostatectomy specimens. (2008) (24)
- Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. (2019) (23)
- The utility of immunostaining for NUT, GAGE7 and NY‐ESO‐1 in the diagnosis of spermatocytic seminoma (2014) (22)
- Establishment and characterization of a novel cell line derived from human thymoma AB tumor (2012) (21)
- Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer (2011) (20)
- Sebaceous carcinoma of the nipple (2008) (19)
- Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer. (2016) (19)
- Tissue Distribution of the Lipocalin Alpha-1 Microglobulin in the Developing Human Fetus (2000) (19)
- Determining PD-L1 Status in Patients with Triple-Negative Breast Cancer: Lessons Learned from IMpassion130. (2021) (19)
- Genotypic characterization of phenotypically defined triple-negative breast cancer. (2009) (18)
- ColoType: a forty gene signature for consensus molecular subtyping of colorectal cancer tumors using whole-genome assay or targeted RNA-sequencing (2020) (18)
- Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes (2010) (18)
- Invasion in breast lesions: the role of the epithelial–stroma barrier (2018) (18)
- Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. (2019) (18)
- Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers (2019) (17)
- Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis (2019) (17)
- Musculoskeletal histoplasmosis. A case report and review of the literature. (2001) (17)
- Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer (2022) (17)
- Molecular Pathology of Breast Cancer (2016) (17)
- ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer (2010) (17)
- Histoplasmosis of the central nervous system. (1992) (17)
- Biomarkers for breast cancer stem cells: the challenges ahead. (2011) (17)
- Expression of high-molecular-weight cytokeratin (34βE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast (2010) (16)
- Milestones in the Discovery of HER2 Proto-Oncogene and Trastuzumab (Herceptin™) (2008) (16)
- Pleomorphic hyalinizing angiectatic tumor of renal hilum. (2012) (16)
- Apoptosis in spermatocytic and usual seminomas: a light microscopic and immunohistochemical study (2007) (15)
- Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study. (2012) (15)
- Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings (2019) (15)
- Phenotypic plasticity in normal breast derived epithelial cells (2014) (15)
- EP1: a novel rabbit monoclonal antibody for detection of oestrogen receptor α (2013) (14)
- Amplified in breast cancer 1 expression in breast cancer (2008) (14)
- Adverse association of expressed vascular endothelial growth factor (VEGF) with long-term outcome of stage I-III breast cancer (BrCa), with co-expression data of VEGF and Her2, Cox2, uPA and ER. Results from the British Columbia Tissue Microarray Project. (2004) (13)
- Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial (2019) (13)
- Abstract S1-07: Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 (2013) (13)
- Immune-Mediated Diseases and Immunodeficiencies Associated with Thymic Epithelial Neoplasms (2012) (13)
- Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer-Clinical Notice (2010) (13)
- The EP1 subtype of prostaglandin E2 receptor: role in keratinocyte differentiation and expression in non-melanoma skin cancer. (2009) (12)
- A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC). (2004) (12)
- Differential gene expression profiling of esophageal adenocarcinoma. (2009) (12)
- Ductal lavage and its histopathologic basis: A cautionary tale (2004) (12)
- Gene expression analysis for prediction of early brain metastasis (BM) in HER2-positive (HER2+) breast cancer patients (pts) (2008) (12)
- A Mexican man with “too much blood” (2003) (12)
- A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study (2021) (11)
- Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. (2020) (11)
- Abstract GS5-02: Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): Preplanned correlative results from clinical trial BRE12-158 (2020) (11)
- Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer (2018) (11)
- Conjunctival Squamous Cell Carcinoma Due to Ocular Prostheses: A Case Report and Review of Literature (2010) (11)
- A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. (2019) (11)
- Intraductal hepatocellular carcinoma with normal liver--case report. (1991) (11)
- Giant Cell Polymyositis and Myocarditis in a Patient With Thymoma and Myasthenia Gravis: A Postviral Autoimmune Process? (2018) (11)
- ANTXR 1 , a stem cell enriched functional biomarker , connects collagen signaling to cancer stem-like cells and metastasis in breast cancer (2013) (11)
- Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer (2014) (10)
- NUT midline carcinomas in the thymic region (2014) (10)
- Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya (2017) (10)
- EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer. (2019) (10)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
- Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). (2020) (10)
- Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma. (2014) (9)
- Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). (2021) (9)
- 13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer. (2012) (9)
- Loss of BRCA1 expression in sporadic male breast carcinoma (2004) (9)
- EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor–Positive Breast Cancer (2019) (9)
- Sulindac prevents carcinogen-induced intrahepatic cholangiocarcinoma formation in vivo. (2009) (9)
- Randomized phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal, metastatic breast cancer. (2016) (9)
- Pathologic quiz case. Colon biopsy in a patient with diarrhea--Possible etiologic agent. (2001) (9)
- Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. (2008) (8)
- Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast (2021) (8)
- Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer (2021) (8)
- Pathologic quiz case: a 42-year-old man with right facial swelling and weakness. Dedifferentiated acinic cell carcinoma of the parotid gland. (2004) (8)
- Non-hodgkin malignant lymphoma with tissue neutrophilia: a report of 3 cases. (2000) (8)
- FOXP3 expression and nodal metastasis of breast cancer (2013) (8)
- 10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features. (2012) (8)
- Role of AKT isotypes in breast cancer (2013) (7)
- Pathologic quiz case. Vaginal wall mass in a 47-year-old woman. Vaginal rhabdomyoma. (2002) (7)
- TP53 Status and Estrogen Receptor-beta in Triple Negative Breast Cancer: Company matters. (2019) (7)
- BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer (2021) (7)
- A novel biomarker for the detection of esophageal adenocarcinoma. (2007) (7)
- Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study (2022) (7)
- Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study (2022) (7)
- The prognostic value of architectural patterns in a study of 37 type AB thymomas (2014) (7)
- The Birth of an Adenoid Cystic Carcinoma (2015) (7)
- HER2 concordance between central laboratory immunohistochemistry and quantitative reverse transcription polymerase chain reaction in Intergroup Trial E2197 (2008) (6)
- Tumour‐infiltrating lymphocytes in ductal carcinoma in situ (DCIS)—assessment with three different methodologies and correlation with Oncotype DX DCIS Score (2020) (6)
- NUT Midline Carcinoma Masquerading As a Thymic Carcinoma. (2016) (6)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
- COX-2 Expression Does Not Correlate with Microvessel Density in Breast Cancer (2009) (6)
- Assessment of variability in diagnosing "atypia" in columnar cell lesions (CCL) of the breast (2005) (5)
- Pathologic Quiz Case: Vaginal Wall Mass in a 47-Year-Old Woman (2009) (5)
- Refined estimates of local recurrence risks and the impact of the DCIS score adjusting for clinico-pathological features: Meta-analysis of E5194 and Ontario DCIS cohort studies. (2017) (5)
- Leiomyosarcoma of the Penis Presenting as a Cutaneous Lesion (2008) (5)
- Single-cell screening and quantification of transcripts in cancer tissues by second-harmonic generation microscopy (2015) (5)
- Immunohistochemistry cocktails are here to stay: Center for Medicare and Medicaid Services should revise its new reimbursement policy. (2012) (5)
- Equivalency of RT-PCR and immunohistochemistry: fact or factoid (2009) (5)
- Multiplexed Protein Analysis (2014) (5)
- NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC). (2018) (4)
- GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer. (2009) (4)
- PARP inhibition after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier Oncology Group BRE09-146. (2011) (4)
- The diagnosis and management of pre-invasive breast disease: another point of view (2003) (4)
- Concordance of local and central laboratory hormone and HER2 receptor status in ECOG 2197 (2007) (4)
- Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome (2013) (4)
- Abstract P1-03-02: “Normal” tissue adjacent to breast cancer is not normal (2012) (4)
- Pathologic Quiz Case: A 42-Year-Old Man With Right Facial Swelling and Weakness (2009) (4)
- Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type (2021) (4)
- Pilot trial assessing the feasibility of intra-ductal delivery of epirubicin (epi)-containing nanoparticles (NP) via InDuct@ Breast Microcatheter (IDBM). (2004) (4)
- Alpha-fetoprotein production by rhabdomyosarcoma of the urinary bladder. (1992) (4)
- RAD51 and brain metastases (BM) in patients (pts) with HER2+ breast cancer. (2011) (3)
- Abstract P5-02-01: Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group study (2020) (3)
- Breast Implant Capsule-Associated Squamous Cell Carcinoma: Report of 2 Patients (2022) (3)
- Large central acellular zones in breast carcinomas do not connote a bad prognosis (2001) (3)
- Thymic Hyperplasia with Lymphoepithelial Sialadenitis (LESA)-Like Features: Strong Association with Lymphomas and Non-Myasthenic Autoimmune Diseases (2021) (3)
- AJCC 8th edition—A step forward (2020) (3)
- Prognostic factors in invasive breast carcinoma: Do new molecular techniques/profiling add significantly to traditional histological factors? (2007) (3)
- Does tumor size trump biology? (2010) (3)
- Spatially variant immune infiltration scoring in human cancer tissues (2022) (3)
- Breast cancer prognostic markers: where are we now? (2012) (3)
- Sentinel Lymph Node Biopsy (2012) (3)
- VEGFA amplification/deletion in human breast tumors. (2010) (3)
- Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130 (2017) (3)
- Abstract P5-04-03: Deconvoluting immune cell populations using ‘in silico flow cytometry’ with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC (2015) (3)
- Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). (2021) (3)
- Is conservative management of ductal carcinoma in situ risky? (2022) (3)
- Breast mass in a patient with ovarian cancer: a case report. (2009) (3)
- Pilot trial assessing the feasibility of intra-ductal delivery of epirubicin (epi)-containing nanoparticles (NP) via InDuct@ Breast Microcatheter (IDBM) (2004) (3)
- Abstract P2-06-05: LINC00478: A novel tumor suppressor in breast cancer (2016) (3)
- A proprietary multianalyte test for predicting extreme resistance to neoadjuvant 5-FU based chemoradiation (CTRT) in esophageal adenocarcinoma (EC). (2014) (3)
- Prospective study of magnetic resonance imaging (MRI) and multiparameter gene expression assay in ductal carcinoma in situ (DCIS): A trial of the ECOG-ACRIN Cancer Research Group (E4112). (2017) (2)
- Ductal carcinoma in situ of breast: from molecular etiology to therapeutic management. (2022) (2)
- Gene Expression Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast Cancer: Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor Pathway and Other Pathways. (2009) (2)
- The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance. (2017) (2)
- OT3-01-05: PARP Inhibition after Preoperative Chemotherapy in Patients with Triple-Negative Breast Cancer (TNBC) or Known BRCA 1/2 Mutations: Hoosier Oncology Group BRE09-146. (2011) (2)
- Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor–Positive, Early Breast Cancer (2019) (2)
- Prospective prediction of resistance to neoadjuvant therapy in patients with locoregional esophageal adenocarcinoma (2015) (2)
- EarlyR-A Robust Gene Expression Signature for Predicting Outcomes of ER+ Breast Cancer (2018) (2)
- Breast cancer prognostic markers: an overview of a changing menu. (2015) (2)
- Promise of computational systems biology for cancer clinical trials: the voyage to be realized? (2010) (2)
- Immunohistochemistry cocktails are here to stay: Center of Medicare and Medicaid Services should revise its new reimbursement policy. (2012) (2)
- INDUCT: A risk score to predict relapse in estrogen-receptor–positive breast cancer. (2014) (2)
- Abstract P6-09-09: Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis (2017) (2)
- Abstract P6-13-01: Local excision without radiation for ductal carcinoma in situ: 12-year results from the ECOG E5194 study (2015) (2)
- Role of tumor infiltrating lymphocytes (TILs) in HER2+ metastatic breast cancers (MBC) treated with trastuzumab emtansine (T-DM1) or lapatinib plus capecitabine (L+C) (EMILIA Trial). (2016) (2)
- Counterpoint: cancer stem cells: nonbelievers' viewpoint. (2013) (2)
- Delivery of Therapeutic Nanoshells to Hypoxic Areas of Tumors Using a Cellular Trojan Horse. (2009) (2)
- EarlyR-A Robust Gene Expression Signature for Predicting Outcomes of ER+ Breast Cancer (2018) (2)
- A phase II study of buparlisib in relapsed or refractory thymomas (2022) (2)
- Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer. (2022) (2)
- Malignant Brenner tumor mimicking a primary squamous cell carcinoma of the cervix. (1999) (2)
- Chapter 26 – Other Malignant Lesions of the Breast (2006) (2)
- Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313). (2017) (2)
- Predictive Biomarkers and Targeted Therapies in Breast Cancer (2018) (1)
- Characteristics of raloxifene-stimulated breast tumors in vivo (2001) (1)
- Diindolylmethane inhibits indoleamine 2,3-dioxygenase activity in breast cancer cells (2005) (1)
- American Society of Clinical Oncology/College ofAmerican Pathologists guideline recommendations forimmunohistochemical testing of estrogen andprogesterone receptors in breast cancer (2010) (1)
- Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank (2014) (1)
- Opportunistic infections in a patient with HIV and thymoma. (2013) (1)
- Tumor marker assessment: Points to ponder (2011) (1)
- P1.14-17 Identification of Molecular Subtypes of Thymic Epithelial Tumors and Novel Treatments Using a Computational Biological Model (2018) (1)
- Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. (2021) (1)
- Abstract P3-02-12: Impact of magnetic resonance imaging on conversion from wide local excision to mastectomy in patients with ductal carcinoma in situ: First results from the ECOG-ACRIN 4112 prospective study (2017) (1)
- Abstract 1175: Persistent upregulation of U6 small RNA in the serum of breast cancer patients (2011) (1)
- Molecular characteristics of matched brain metastasis (BM) versus the primary breast cancer (PBC). (2009) (1)
- Thymic Carcinomas and Second Malignancies: A Single-Center Review (2021) (1)
- 170P β2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled on the NCCTG-N9831 (Alliance) trial (2020) (1)
- Abstract 4589: Overexpression of RAD51 promotes brain metastases from breast cancer. (2013) (1)
- Protein Profiling of Breast Cancer for Treatment Decision-Making. (2022) (1)
- Re. article entitled ‘Expression of CD31 by cells of extensive ductal in situ and invasive carcinomas of the breast’ (2002) (1)
- NUT protein is not expressed in undifferentiated (anaplastic) thyroid carcinoma (2013) (1)
- Phenotypic plasticity in normal breast derived epithelial cells (2014) (1)
- Immunological markers of outcome of non-small cell lung cancer (2005) (1)
- Abstract PS10-26: An initial safety study of gedatolisib plus cofetuzumab pelidotin for metastatic triple-negative breast cancer (2021) (1)
- Next-generation sequencing of thymic malignancies. (2012) (1)
- Telomerase TemplateAntagonist GRN 163 L Disrupts Telomere Maintenance , Tumor Growth , andMetastasis of Breast Cancer (2006) (1)
- A proprietary multi-analyte test to predict neoadjuvant treatment response for esophageal and rectal adenocarcinoma patients. (2014) (1)
- The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance (2017) (1)
- H. Pylori Serology Reduces the Workload from Direct Access Endoscopy (1992) (1)
- Prediction of long-term survival using expression of FOXA1, a determinant of estrogen response domains in breast cancer. (2006) (1)
- Abstract 4490: INK128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in a VEGF-reinforced murine model of breast cancer and enhances efficacy of bevacizumab (2010) (1)
- Predictive utility of progesterone receptor (PR) and multigene expression in identifying benefit from adjuvant doxorubicin plus cyclophosphamide (AC) or docetaxel (AT) in intergroup trial E2197 (2008) (1)
- Food for Thought (2005) (1)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast (2022) (1)
- Molecular-based Testing in Breast Disease for Therapeutic Decisions (2012) (1)
- Abstract 5306: Overexpression of RAD51 promotes brain metastases from breast cancer (2012) (1)
- RespondR signature to predict potential alternative therapies for taxane resistant triple-negative breast cancer patients. (2016) (1)
- A 19-gene prognostic GEP signature (DecisionDx-Thymoma) to determine metastatic risk associated with thymomas. (2012) (1)
- Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy. (2010) (1)
- Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration (2016) (0)
- CMS-PDX: A 20-gene genomic panel to predict consensus molecular subtypes in patient-derived xenografts (PDX) of colorectal cancer. (2019) (0)
- Thank you to our reviewers (2020) (0)
- Acknowledgement of reviewers 2019 (2020) (0)
- Co-expression of ER and c-erb B2 in breast cancer (2001) (0)
- Abstract P6-15-03: Inflammatory breast cancer (IBC) defined: Proposed common diagnostic criteria and scoring - Moving beyond the subjective ‘clinical diagnosis’ of IBC to advance research (2020) (0)
- Indiana Center for Breast Cancer Research (2014) (0)
- Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma (2021) (0)
- Abstract P1-06-08: Independent validation of EarlyR gene signature in E2197: A randomized clinical trial comparing doxorubicin plus docetaxel to doxorubicin plus cyclophosphamide as adjuvant chemotherapy in breast cancer (2018) (0)
- AB007. OS02.01. The integrated genomic landscape of thymic epithelial tumors: a report by the TCGA research network (2017) (0)
- Abstract 2109: A novel role forESRP1in regulating proliferation in therapy-resistant ER-positive breast cancer (2019) (0)
- Author's response to reviews Title: SLUG and Human Chorionic Gondadotropin Induce Breast Cells With "Stem Cell-Like" Properties Authors: (2010) (0)
- Steroid Hormone and Nuclear Receptor Signaling Pathways (2018) (0)
- Intrinsic radiomics phenotypes of DCI from breast DCE-MRI: demonstrating feasibility in interim analysis of the ECOG-ACRIN E4112 trial (2021) (0)
- Molecular predictors of metastases and stage of thymoma. (2011) (0)
- RNA-sequencing of residual triple-negative breast cancers after neoadjuvant chemotherapy compared to matched pretreatment biopsies from the Hoosier Oncology Group trial BRE09-146. (2014) (0)
- Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer (2022) (0)
- Abstract P5-04-03: Aggressiveness of epithelial cancers is independent of epithelial-to-mesenchymal transition (2018) (0)
- Epigenetic Mechanism in Breast Cancer (2016) (0)
- DNA plonity in papillary lesions of the duodenum and ampulla of vater (1998) (0)
- RespondR: A genomic score to predict the responsiveness of triple-negative breast cancer patients to chemotherapy. (2015) (0)
- Fibroblastic sarcomas of the mediastinum (2020) (0)
- Paget’s Disease of the Breast (2008) (0)
- Expression of a cancer associated isoform of PCNA in breast cancer has implications as a potential biomarker (2007) (0)
- Validation of FOXA1 as a Prognostic Marker in Breast Cancer in a Large Population-Based Tissue Microarray. (2009) (0)
- 2015 IMJ Reviewers (2016) (0)
- Chemobiological screening for identification of molecular targets for thymic epithelial cancers. (2010) (0)
- Referee acknowledgement for 2019 (2020) (0)
- Providing CLARITY: 3D Imaging of Biomarkers in Tumor Samples (2018) (0)
- Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues (2019) (0)
- Immune-Mediated Diseases and Immunodeficiencies Associated with Thymic Epithelial Neoplasms (2012) (0)
- FOXP3 expression and nodal metastasis of breast cancer (2013) (0)
- Artificial intelligence in breast pathology – dawn of a new era (2023) (0)
- Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer (2021) (0)
- Predicting Breast Cancer Events in Ductal Carcinoma In Situ (DCIS) Using Generative Adversarial Network Augmented Deep Learning Model (2023) (0)
- Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer (2022) (0)
- F 270 ROLE OF HELICOBACTER PYLORI SEROLOGjY IN SCREENING PRIOR TO DIRECT ACCESS ENDOSCOPY (2006) (0)
- Two Instrument Comparison of Reagents From a US FDA-Approved Assay for the Assessment of Ki-67 in High-Risk Early Breast Cancer (2022) (0)
- The Role of ESRP1 in the Regulation of PHGDH in Estrogen Receptor-Positive Breast Cancer. (2023) (0)
- Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers (2019) (0)
- Abstract P1-04-14: Predicting the likelihood of response in PDL-1 positive metastatic triple negative breast cancer treated with an immune checkpoint inhibitor (2023) (0)
- Referee acknowledgement for 2020 (2021) (0)
- High Interobserver Variability among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction and Esophageal Adenocarcinoma. (2023) (0)
- A predictor of response in HER2+ breast cancer-at last! (2022) (0)
- Abstract P6-04-13: Centralized adequacy assessment of ductal carcinoma in situ samples for the COMET study (AFT-25) (2023) (0)
- Is conservative management of ductal carcinoma in situ risky? (2022) (0)
- Proceedings of the 3rd Indian Cancer Genome Atlas Conference 2022: Biobanking to Omics: Collecting the Global Experience. (2023) (0)
- Abstract P4-08-17: Expression score (Escore) for the prediction of likelihood of recurrence of DCIS (2019) (0)
- The Pandemic as a Catalyst for Digital Pathology Adoption as an LDT (2022) (0)
- Abstract P6-04-10: Recurrence Prediction in Ductal Carcinoma In Situ (DCIS) Patients from Tissue Microarrays (TMAs) (2023) (0)
- 560 Infusional 5-fluorouracil with alpha interferon as a palliative treatment for patients with symptomatic malignant neuroendocrine tumours (1995) (0)
- Abstract GS1-05: Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates (2023) (0)
- ColotypeR gene signature predicts response to cetuximab in colorectal cancer metastases. (2019) (0)
- Abstract P1-08-35: Stromal tumor infiltrating lymphocytes analysis by race and ethnicity in triple negative breast cancers from 2 phase III randomized adjuvant breast cancer trials: ECOG-ACRIN E2197 and E1199 (2022) (0)
- Racial Disparities in Breast Cancer Outcomes: Are They Predestined? (2011) (0)
- Non-Hodgkin Malignant Lymphoma With Tissue Neutrophilia (2009) (0)
- Abstract B37: Overcoming resistance to chemotherapy using ZNF217 as a predictive marker and therapeutic target of breast cancer (2016) (0)
- Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer sub jects (2006) (0)
- A morphological classification of breast in menstrual cycle (2001) (0)
- P3-04-02: Bevacizumab Treatment Alters Intrinsic Subtypes in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer. (2011) (0)
- Abstract B47: The role of ZNF217 in the development of breast cancer chemoresistance (2015) (0)
- Estrogen- and progesterone-receptor status in breast cancer: Immunohistochemistry and quantitative reverse transcription-polymerase chain reaction assays show equivalency (2008) (0)
- AB001. OS01.01. Post op radiation may be detrimental in thymoma but not in thymic carcinoma tumors (2017) (0)
- Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. (2009) (0)
- Noncoding RNAs in breast cancer (2016) (0)
- Multi-Protein Signatures in Ductal Carcinoma In Situ (DCIS) of Breast (2019) (0)
- Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB 7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer (2011) (0)
- FOXA1 Expression in Urothelial Carcinoma of the Renal pelvis (2012) (0)
- Abstract P1-06-02: Impact of heterogeneity of DCIS on immune cell infiltrations (2017) (0)
- Phosphopeptide mapping of DLC1 in ER+ breast cancer reveals AMOTL2, a key hippo pathway component, as an important target. (2017) (0)
- ER+ high-grade breast carcinomas do not show myoepithelial differentiation (2001) (0)
- CYP3A5 gene expression is associated with early recurrence of non-small cell lung cancer (2008) (0)
- D-Dimer Measurements Unhelpful for Ruling In DIC (2000) (0)
- Abstract 4628: Profiling the tumor microenvironments of triple- and quadruple-negative breast cancers (2023) (0)
- Abstract P2-07-04: Molecular regulators of resistance and relapse in chemorefractory triple-negative breast cancers (2018) (0)
- Uraemia--a rare presentation of non-Hodgkin's lymphoma. (1990) (0)
- Decreased T cell infiltration and lymphocyte/dendritic cell/monocyte gene expression as well as increased Cyp3A5 mRNA predicts early recurrence of non-small cell lung cancer (NSCLC) following surgical resection. (2004) (0)
- 2648 Novel DNA methylation therapeutic targets in urothelial carcinoma (UC) from patients with paired metachronous primary and metastatic tumors (2015) (0)
- 5BA Identification of gene expression profiles that predict response to HER2-targeted therapy (2009) (0)
- Abstract 3851: Molecular profiling of aggressive breast cancer in a unique patient population from Kenya (2014) (0)
- How repoducible is the diagnosis of flat epithelial atypia of the breast (2005) (0)
- CXCR4 alters ID family and ITF2B/E2-2/TCF-4 dynamics to confer invasive phenotype to breast cancer cells. (2009) (0)
- 5 Featured Laboratory (2008) (0)
- Novel Image Analysis to Link Sub-Nuclear Distribution of Proteins with Cell Phenotype in Mammary Cancer (2003) (0)
- Letter to the Editor (2008) (0)
- Abstract P5-09-09: ESRP1 and ESRP2 expression in tamoxifen resistance (2013) (0)
- Abstract 1097: Knockdown of splicing factor ESRP1 affects multiple splicing factors (2015) (0)
- Abstract P5-03-02: Three-dimensional (3D) imaging of biomarkers in human core needle biopsies of normal and cancerous breast tissue (2018) (0)
- Postoperative radiation for tumor control and overall survival in thymic epithelial tumors (TET): A matched-pair analysis. (2017) (0)
- Abstract 2695: Quantitative phosphoproteome analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor-positive breast cancer (2018) (0)
- APhysiologic Imaging Pilot Study of Breast Cancer (2005) (0)
- Abstract P2-10-06: Ethnicity-dependent alternative RNA splicing variations of estrogen receptor in breast cancer (2020) (0)
- Abstract 5106: Unexpected roles for stromal MMP3 during breast cancer (2016) (0)
- Abstract P6-04-01: Next-Generation Transcriptome Sequencing of the Normal Breast (2010) (0)
- The neuronal cell adhesion molecule L1CAM as a therapeutic targe in breast cancer. (2011) (0)
- Abstract P3-05-20: ESRP1 adds sp(l)ice to endocrine resistance (2015) (0)
- Tissue case-controls: What is normal? (2001) (0)
- P5-06-01: Gene Expression Analysis of Resistance to Bevacizumab in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer. (2011) (0)
- THE INDIANA CENTER FOR BREAST CANCER RESEARCH: PROGRESS REPORT (2013) (0)
- Paraneoplastic syndrome and survival in thymic epithelial tumors (TET): The Indiana University experience. (2017) (0)
- P2-13-01: Gene Profiling of Whole Blood May Identify Patients with BRCA Mutations. (2011) (0)
- Abstract 1478: The DNA double-strand break repair genes BARD1 and RAD51 as molecular targets for brain metastases from breast cancer (2011) (0)
- Factors influencing outcome in thymic epithelial tumors (TET). (2012) (0)
- Prognostic and Predictive Gene Expression Signatures in Breast Cancer (2016) (0)
- Regulatory T cells (T-Regs) in breast cancer sentinel nodes (SN): FOXP3 expression analysis (2008) (0)
- Association of the t(12;22)(q13;q12) EWS/ATF1 Rearrangement With Polyphenotypic Round Cell Sarcoma of Bone: A Case Report (2006) (0)
- Abstract 4187: Splicing factorsESRP1/ESRP2as regulators of endocrine resistance in breast cancer (2014) (0)
- Abstract P2-08-02: Chronic inflammation and the development of breast cancer (2013) (0)
- P5-05-02: Phenotypic Plasticity in the Normal Breast. (2011) (0)
- Abstract P2-05-03: Novel driver genetic alterations in MYB-NFIB-negative breast adenoid cystic carcinomas (2018) (0)
- Abstract 3322: Phenotypic plasticity in the normal breast (2012) (0)
- Identification of novel immunomodulatory tumor biology through comprehensive characterization of a metastases-specific epigenome in patients with metachronous primary and metastatic urothelial carcinoma (UC) tumor pairs. (2016) (0)
- 542 A Proprietary Immunohistochemistry (IHC)-Based Test That Accurately Predicts Extreme Resistance to Fluorouracil (5FU)-Based Neoadjuvant Chemoradiation (Neoctrt) Therapy in Patients of Esophageal Adenocarcinoma (EAC) (2014) (0)
- APhysiologic Imaging Pilot Study of Breast Cancer Treatedwith AZD 2171 (2005) (0)
- Reply to C. Shah et al. (2016) (0)
- In silico identification of an epithelial core signature in human tumors. (2012) (0)
- Abstract 4206: Identification of transcriptional regulatory motifs that control gene expression in premenopausal women with previous history of breast cancer (2012) (0)
- Reply to J.M. Guinebretiere and L. Arnould et al (2009) (0)
- Abstract 4858: Next-generation whole transcriptome sequencing of thymic malignancies (2011) (0)
- The Indiana Center for Breast Cancer Research: Progress towards a SPORE Proposal (2012) (0)
- Abstract GS3-05: Classification of triple negative breast cancer (TNBC) by DNA damage immune response (DDIR) signature and homologous recombination deficiency (HRD) status: Analysis of SWOG S9313 adjuvant trial (2021) (0)
- The effects of Oncotype DX recurrence scores on chemotherapy receipt in a multi-institutional breast cancer cohort. (2010) (0)
- Prediction of brain relapse by gene expression analysis in HER2-positive metastatic breast cancer patients (2008) (0)
- Control of luminal type A intrinsic subtype enriched transcription factor network by insulin: implications of diabetes on breast cancer classification. (2009) (0)
- FOXA1 (forkhead box A1) (2011) (0)
- Factors affecting survival of patients with Masaoka stage IV thymic epithelial tumors (TET). (2012) (0)
- Abstract 3489: In silico analysis of angiogenesis pathway as a prognostic tool in breast cancer (2011) (0)
- Referee Acknowledgement for 2013 (2014) (0)
- Lymphangiogenesis in breast cancer [4] (2006) (0)
- Prediction of late relapse in patients with estrogen-receptor–positive breast cancer. (2014) (0)
- Abstract P4-12-01: Independent validation of EarlyR gene signature in BIG 1-98: A randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer (2017) (0)
- Effect of bariatric surgery on breast tissue and biomarkers in obese women at increased risk for breast cancer. (2017) (0)
- Abstract PD9-10: BRE12-158: A post-neoadjuvant, randomized phase 2 trial of personalized therapy vs. treatment of physician’s choice for patients with residual triple negative breast cancer (2022) (0)
- A gene signature to determine metastatic behavior in thymic carcinoma. (2013) (0)
- Pathology for breast surgeons (2023) (0)
- Histopathology would like to thank the following reviewers for their help in 2005: (2005) (0)
- Secretion of MIP by myeloma cells as a cause of lytic bone lesions (2004) (0)
- Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx (2019) (0)
- Histopathology would like to thank the following reviewers for their help in 2009: (2009) (0)
- Abstract PD1-7: Differential expression of innate and adaptive immune responses in TNBC outcome (2015) (0)
- Abstract 230: Connectivity-map analyses identify FDA-approved drugs targeting breast cancer stem cells. (2013) (0)
- Correlation of FOXA1 expression with Oncotype Dx recurrence scores. (2009) (0)
- Applied Proteomics in Breast Cancer (2016) (0)
- Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies: HOG LUN 07-130. (2014) (0)
- Harnessing the power of multi-institutional databases to improve the understanding and treatment of thymic epithelial tumors (2018) (0)
- Breast calcifications following electrical defibrillation: An unusual mammographic appearance (2015) (0)
- Abstract P3-05-15: Divergent activation of AKT1 and AKT2 isoforms downstream of PI3K mutation impacts response of breast cancer cells to estradiol and PI3K inhibitors (2015) (0)
- P5-21-02: The Susan G. Komen for the Cure® Tissue Bank at the IU Simon Cancer Center: The Source for Normal Breast Tissue and Biospecimens. (2009) (0)
- The Role of PRIP in Breast Cancer (2002) (0)
- AB012. OS03.02. Paraneoplastic syndrome and survival in thymic epithelial tumors the IU experience (2017) (0)
- Histopathology would like to thank the following reviewers for their help in 2006: (2006) (0)
- Genomic insights on the structure , function and disease associations of lncRNAs 127 (2015) (0)
- Prognostic ability of CD44 expression in ER-positive breast cancer. (2014) (0)
- Abstract P4-09-12: Quantitative image features of nuclear and tubule architecture distinguish high and low oncotype DX risk categories of ductal carcinoma in situ from H&E tissue images (2018) (0)
- Abstract 1226: Targeting BTK family in ER+ breast cancer with Ibrutinib for personalized precision medicine: a double-edged sword (2017) (0)
- Food for thought. (2019) (0)
- ColotypeR: A tool to classify colon cancers by consensus molecular subtype and subtype-specific risk of recurrence. (2018) (0)
- Referee Acknowledgement for 2016 (2017) (0)
- Chapter 27 – Diseases of the Male Breast (2006) (0)
- RespondR signature to predict response in TNBC patients treated with adjuvant taxane based chemotherapy in TCGA dataset. (2016) (0)
- EarlyR genomic signature to predict pathological complete response following neoadjuvant anthracycline-taxane chemotherapy in estrogen-receptor positive (ER+) breast cancer. (2017) (0)
- Quantification of spatial pharmacogene expression heterogeneity in breast tumors (2021) (0)
- A 19-gene prognostic GEP signature to determine metastatic risk associated with thymomas. (2012) (0)
- Abstract 2667: L1CAM neural adhesion molecule is overexpressed in human brain metastases of breast cancer and contributes to colony formation efficiency (2011) (0)
- Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer (2011) (0)
- Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings (2019) (0)
- Serological Diagnosis of Eradication of H. Pylori Infection (1992) (0)
This paper list is powered by the following services:
Other Resources About Sunil S. Badve
What Schools Are Affiliated With Sunil S. Badve?
Sunil S. Badve is affiliated with the following schools:
